New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis

Current Rheumatology Reports

Volumn 16, Issue 7, 2014, Pages

  Alemo Munters, Li ^a,c   Alexanderson, Helene ^a,b   Crofford, Leslie J ^c   Lundberg, Ingrid E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Aerobic capacity; Aerobic metabolism; Dermatomyositis; Disease activity; Exercise adaptations; Idiopathic inflammatory myopathies; Inclusion body myositis; Muscle function; Physical exercise; Polymyositis; Skeletal muscle

Indexed keywords

AEROBIC CAPACITY; AEROBIC EXERCISE; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENDURANCE TRAINING; FUNCTIONAL ASSESSMENT; HUMAN; MUSCLE EXERCISE; MUSCLE FUNCTION; MUSCLE STRENGTH; MYOSITIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT SAFETY; POLYMYOSITIS; REVIEW; SKELETAL MUSCLE; THERAPY EFFECT; TREATMENT RESPONSE; EXERCISE; KINESIOTHERAPY; PHYSIOLOGY; PROCEDURES;

EXERCISE; EXERCISE THERAPY; HUMANS; MUSCLE, SKELETAL; MYOSITIS;

EID: 84901610031     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-014-0429-4     Document Type: Review

References (55)

1. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother. 2009;10:1183-90.
2. Harris-Love MO et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford). 2009;48:134-9.
3. Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2005;17:701-6. (Pubitemid 41546487)
4. Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol. 2011;7:297-306.
5. Miller FW. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis. 2012;71 Suppl 2:i82-5.
6. Marie I et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230-7. (Pubitemid 32947868)
7. Sultan SM et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford). 2002;41:22-6. (Pubitemid 34537916)
8. Ponyi A et al. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford). 2005;44:83-8. (Pubitemid 40124337)
9. Bronner IM et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis. 2006;65:1456-61. (Pubitemid 44629122)
10. Regardt M et al. Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study. Rheumatology (Oxford). 2011;50:578-85.
11. Dimachkie MM, Barohn RJ. Inclusion body myositis. Curr Neurol Neurosci Rep. 2013;13:321.
12. Cox FM et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford). 2011;50:1153-61.
13. Cortese A et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord : NMD. 2013;23:404-12.
14. Greenberg SA. Biomarkers of inclusion body myositis. Curr Opin Rheumatol. 2013;25:753-62.
15. Sadjadi R, Rose MR. What determines quality of life in inclusion body myositis? J Neurol Neurosurg Psychiatry. 2010;81:1164-6.
16. Lundberg IE. The physiology of inflammatory myopathies: an overview. Acta Physiol Scand. 2001;171:207-13. (Pubitemid 32823788)
17. Nader GA, Lundberg IE. Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. Curr Opin Rheumatol. 2009;21:599-603.
18. Hanaoka BY, Peterson CA, Crofford LJ. Glucocorticoid effects on skeletal muscle: benefit and risk in patients with autoimmune inflammatory rheumatoid diseases. Expert Rev Clin Immunol. 2012;8:695-7.
19. Rayavarapu S, Coley W, Nagaraju K. An update on pathogenic mechanisms of inflammatory myopathies. Curr Opin Rheumatol. 2011;23:579-84.
20. Rayavarapu S, Coley W, Nagaraju K. Endoplasmic reticulum stress in skeletal muscle homeostasis and disease. Curr Rheumatol Rep. 2012;14:238-43.
21. Henriques-Pons A, Nagaraju K. Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis. Curr Opin Rheumatol. 2009;21:581-7.
22. Loell I, Lundberg IE. Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies? J Intern Med. 2011;269:243-57.
23. Nader GA et al. A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis. Mol Med. 2010;16:455-64.
24. Westerblad H, Bruton JD, Katz A. Skeletal muscle: energy metabolism, fiber types, fatigue and adaptability. Exp Cell Res. 2010;316:3093-9.
25. Booth FW, Thomason DB. Molecular and cellular adaptation of muscle in response to exercise: perspectives of various models. Physiol Rev. 1991;71:541-85.
26. Hepple RT et al. Resistance and aerobic training in older men: effects on VO2peak and the capillary supply to skeletal muscle. J Appl Physiol Respir Environ Exerc Physiol. 1997;82:1305-10. (Pubitemid 27172334)
27. Hood DA. Invited Review: contractile activity-induced mitochondrial biogenesis in skeletal muscle. J Appl Physiol Respir Environ Exerc Physiol. 2001;90:1137-57. (Pubitemid 32171405)
28. McCarthy JJ, Esser RA. Skeletal Muscle Adaptation to Exercise. In: Hill J, editor. Muscle Fundamental Biology and Mechanisms of Disease: Elsevier Inc; 2012: 911-20.
29. Okuma H et al. Muscle metabolism in patients with polymyositis simultaneously evaluated by using 31P-magnetic resonance spectroscopy and near-infrared spectroscopy. Int J Clin Pract. 2007;61:684-9. (Pubitemid 46449845)
30. Park JH, Olsen NJ. Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. Curr Rheumatol Rep. 2001;3:334-45.
31. Chung YL et al. Urinary levels of creatine and other metabolites in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford). 2003;42:298-303.
32. Dastmalchi M et al. Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum. 2007;57:1303-10. (Pubitemid 47585478)
33. Cea G et al. Reduced oxidative phosphorylation and proton efflux suggest reduced capillary blood supply in skeletal muscle of patients with dermatomyositis and polymyositis: a quantitative 31P-magnetic resonance spectroscopy and MRI study. Brain. 2002;125:1635-45. (Pubitemid 34755177)
34. Grundtman C et al. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum. 2008;58:3224-38.
35. Blume G et al. Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain. 1997;120(Pt 1):39-45. (Pubitemid 27081259)
36. Temiz P, Weihl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci. 2009;278:25-9.
37. Varadhachary AS, Weihl CC, Pestronk A. Mitochondrial pathology in immune and inflammatory myopathies. Curr Opin Rheumatol. 2010;22:651-7.
38. •• Alemo Munters L et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Therapy. 2013;15(R83). This study indicates low aerobic capacity in patients with chronic polymyositis and dermatomyositis compared to healthy controls. Also, a randomized controlled trial suggests that endurance exercise contributes to improvement in exercise performance in these patients through increased aerobic capacityc and within-muscle adaptations such as increased mitochondrial capacity.
39. • Bertolucci F, et al. Abnormal lactate levels in patients with polymyositis and dermatomyositis: the benefits of a specific rehabilitative program. European journal of physical and rehabilitation medicine 2013. This study indicates low aerobic capacity in skeletal muscle in patients with polymyositis or dermatomyositis compared to healthy, and in an open design a shift to aerobic metabolism concurrent with improved muscle perfomance by physical exercise in these patients.
40. Wiesinger GF et al. Aerobic capacity in adult dermatomyositis/ polymyositis patients and healthy controls. Arch Phys Med Rehabil. 2000;81:1-5. (Pubitemid 30036865)
41. Someya F, Mugii N. Limitations to the 6-minute walk test in dermatomyositis with interstitial lung disease in comparison with idiopathic interstitial pneumonia. Clin Med Insights Circ, Respir Pulm Med. 2013;7:1-6.
42. Alexanderson H, Lundberg IE. Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2012;24:201-7.
43. Habers GE, Takken T. Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy - a systematic review. Rheumatology (Oxford). 2011;50:2113-24.
44. Escalante A, Miller L, Beardmore TD. Resistive exercise in the rehabilitation of polymyositis/dermatomyositis. J Rheumatol. 1993;20:1340-4. (Pubitemid 23310986)
45. Alexanderson H et al. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol. 2000;29:295-301. (Pubitemid 32014846)
46. Varju C et al. The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil. 2003;17:83-7. (Pubitemid 36230983)
47. de Salles PV et al. The possible role of physical exercise on the treatment of idiopathic inflammatorymyopathies. Autoimmun Rev. 2009;8:355-9.
48. Perandini LA et al. Exercise as a therapeutic tool to counteract inflammation and clinical symptoms in autoimmune rheumatic diseases. Autoimmun Rev. 2012;12:218-24.
49. •• Alemo Munters L et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup. Arthritis Care Res. 2013;65:1959-68. This randomized controlled trial suggests that a reduction in disease activity and improvement in health by endurance exercise is mediated through improved aerobic capacity.
50. • Alemo Munters L, et al. A Randomized Controlled, Clinical, Histological and mRNA Profiling Pilot Study Of Endurance Exercise In Myositis. Arthritis and rheumatism 2013; [abstract]. This controlled study describes potential mechanisms underlying the benefial effects of endurance exercixe such as increased capillary density in chronic polymyositis or dermatomyositis.
51. Dalise S et al. Intensive aerobic training improves motor performances and oxidative metabolism efficiency in chronic polymyositis: a case report. Neuromuscul Disord : NMD. 2012;22 Suppl 3:S221-5.
52. Hejazi SM, Engkasan JP, Qomi MS. Intensive exercise and a patient in acute phase of polymyositis. J Back Musculoskelet Rehabil. 2012;25:231-4.
53. .• Mattar MA et al. Exercise as an adjuvant treatment in persistent active polymyositis. J Clin Rheumatol : Practical Reports Rheumatic & Musculoskelet Diseases. 2014;20:11-5. This case series study suggests benefical effects of physical exercise and saftey in patients with active polymyositis.
54. •• Alexanderson H, et al. Resistive Home Exercise in Patients with Recent Onset Polymyositis and Dermatomyositis - a Randomized Controlled Single-blinded Study with a 2-Year Follow-up. J Rheumatol. 2014. doi:10.3899/jrheum.131145. This is the first publication to evaluate effects of physical exercise in active polymyositis or dermatomyositis in a randomized controlled trial.
55. Isenberg DA et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford). 2004;43:49-54. (Pubitemid 38088368)